Analysts have clear opinions on KURA.
There are 4 analysts on the Wall offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $28.67 with a high forecast of $30.00 and a low forecast of $27.00. The average price target represents a 344.50% increase from the last price of $6.45.
Kura Oncology, Inc. (KURA) is followed by 4 analysts on the street.
null from rates it a .
Similarly, null of a with a target of .
The consensus on the street is null.
What does Kura Oncology, Inc.(KURA) do ?
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
Kura Oncology, Inc. (KURA) Insider Trades
Multiple company employees have indulged in significant insider trading. Kura Oncology, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
Head of Development, CMO, Gualberto Antonio : S – Sale+OE(-$379,903) of KURA in the trading session of 2019-07-10.
10% Ecor1 Capital Fund Qualified, L.P. : P – Purchase(+$2,901,833) of KURA in the trading session of 2018-12-18.
10% Ecor1 Capital Fund Qualified, L.P. : S – Sale(-$350,064) of Kura Oncology, Inc. in the trading session of 2018-12-17.
Looking for stocks just like KURA?
Based on Wall Street analyst research, several stocks are similar to KURA
– OCUL [Info can be found here: https://www.nasdaq.com/market-activity/stocks/OCUL ]
– SCYX [Info can be found here: https://www.nasdaq.com/market-activity/stocks/SCYX ]
– MRNS [Info can be found here: https://www.nasdaq.com/market-activity/stocks/MRNS ]